Sanofi (SNY) Position Boosted by AMG National Trust Bank
AMG National Trust Bank raised its holdings in shares of Sanofi (NYSE:SNY) by 5.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 54,317 shares of the company’s stock after buying an additional 2,894 shares during the quarter. AMG National Trust Bank’s holdings in Sanofi were worth $2,704,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also bought and sold shares of the stock. Lincluden Management Ltd. grew its position in Sanofi by 4.7% during the third quarter. Lincluden Management Ltd. now owns 64,848 shares of the company’s stock worth $3,229,000 after buying an additional 2,905 shares in the last quarter. Conning Inc. purchased a new position in Sanofi during the third quarter worth about $573,000. Cable Hill Partners LLC purchased a new position in Sanofi during the third quarter worth about $228,000. Crossmark Global Holdings Inc. purchased a new position in Sanofi during the third quarter worth about $4,636,000. Finally, Well Done LLC purchased a new position in Sanofi during the third quarter worth about $407,000. Institutional investors and hedge funds own 9.36% of the company’s stock.
SNY has been the subject of several recent analyst reports. Argus restated a “buy” rating and set a $55.00 target price on shares of Sanofi in a research report on Friday, September 1st. Zacks Investment Research cut Sanofi from a “hold” rating to a “strong sell” rating in a research report on Friday, October 6th. HSBC Holdings plc upgraded Sanofi from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 30th. BidaskClub cut Sanofi from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi in a research report on Friday, September 15th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $53.50.
In other news, major shareholder Sanofi purchased 105,820 shares of the company’s stock in a transaction on Thursday, August 24th. The stock was purchased at an average price of $482.04 per share, with a total value of $51,009,472.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.00% of the company’s stock.
Shares of Sanofi (SNY) traded up $0.33 during mid-day trading on Tuesday, reaching $46.07. The company’s stock had a trading volume of 1,238,668 shares, compared to its average volume of 1,400,000. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.16 and a current ratio of 1.59. Sanofi has a 52-week low of $38.45 and a 52-week high of $50.65. The company has a market capitalization of $115,200.00, a price-to-earnings ratio of 14.43, a P/E/G ratio of 2.03 and a beta of 0.88.
ILLEGAL ACTIVITY NOTICE: “Sanofi (SNY) Position Boosted by AMG National Trust Bank” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/11/07/sanofi-sny-position-boosted-by-amg-national-trust-bank.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.